European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Top Cited Papers
- 30 January 2015
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (4), 619-644
- https://doi.org/10.1111/jdv.12966
Abstract
Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep‐seated, inflamed lesions in the apocrine gland‐bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. A mean disease incidence of 6.0 per 100 000 person‐years and an average prevalence of 1% has been reported in Europe. HS has the highest impact on patients' quality of life among all assessed dermatological diseases. HS is associated with a variety of concomitant and secondary diseases, such as obesity, metabolic syndrome, inflammatory bowel disease, e.g. Crohn's disease, spondyloarthropathy, follicular occlusion syndrome and other hyperergic diseases. The central pathogenic event in HS is believed to be the occlusion of the upper part of the hair follicle leading to a perifollicular lympho‐histiocytic inflammation. A highly significant association between the prevalence of HS and current smoking (Odds ratio 12.55) and overweight (Odds ratio 1.1 for each body mass index unit) has been documented. The European S1 HS guideline suggests that the disease should be treated based on its individual subjective impact and objective severity. Locally recurring lesions can be treated by classical surgery or LASER techniques, whereas medical treatment either as monotherapy or in combination with radical surgery is more appropriate for widely spread lesions. Medical therapy may include antibiotics (clindamycin plus rifampicine, tetracyclines), acitretin and biologics (adalimumab, infliximab). A Hurley severity grade‐relevant treatment of HS is recommended by the expert group following a treatment algorithm. Adjuvant measurements, such as pain management, treatment of superinfections, weight loss and tobacco abstinence have to be considered.Keywords
This publication has 103 references indexed in Scilit:
- Management of Regional Hidradenitis Suppurativa With Vacuum-Assisted Closure and Split Thickness Skin GraftsAnnals of Plastic Surgery, 2011
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Human β-defensin-2 and psoriasin are overexpressed in lesions of acne inversaJournal of the American Academy of Dermatology, 2009
- Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severityJournal of the American Academy of Dermatology, 2009
- A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2009
- The prevalence of hidradenitis suppurativa and its potential precursor lesionsJournal of the American Academy of Dermatology, 1996
- Histology of hidradenitis suppurativaJournal of the American Academy of Dermatology, 1996
- Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healingJournal of the American Academy of Dermatology, 1996
- Successful treatment of hidradenitis suppurativa with acitretinJournal of the American Academy of Dermatology, 1988
- Evaluation of isotretinoin treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 1984